ArticleBriefings in bioinformatics2025
Mapping cancer heterogeneity: a consensus network approach to subtypes and pathways.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We introduce consensus MSClustering, an unsupervised hierarchical network approach that integrates multi-omics data to identify molecular subtypes and conserved pathways across diverse cancers. Using a novel heterogeneity index, we selected 167 key genes with functionally coherent roles validated through Gene Ontology analysis. Applied to 2439 tumors spanning 10 cancer types-and successfully extended to 2675 tumors (12 types) including cases with incomplete molecular data-MSClustering demonstrated: (i) precise classification of major cancer types and breast cancer molecular subtypes; (ii) discovery of novel pan-cancer squamous metaplastic signatures; (iii) exceptional prognostic stratification (log-rank P = 2.3 × 10-46); and (iv) superior performance over existing methods (COCA/SNF) in classification accuracy, cluster robustness, and computational efficiency. The method's multi-scale architecture uniquely resolves breast cancer heterogeneity across biological resolution levels. Pathway analysis further revealed four key oncogenic programs-proteoglycan signaling, chromosomal stability, VEGF-mediated angiogenesis, and drug metabolism-along with disruptions in immune and digestive system functions. This integrative framework marks a significant advancement in cancer genomics by enabling more refined molecular classification, enhanced prognostic insights, and deeper understanding of disease mechanisms. These results highlight the potential of MSClustering to inform the development of clinically relevant biomarkers and support more personalized strategies in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.